We report the cases of three men with severe hyperhomocysteinaemia that was associated with high alcohol intake and which resolved on reduction of alcohol intake. Investigation to identify other obvious causes of the hyperhomocysteinaemia excluded renal failure and vitamin deficiencies. Alcohol as a possible cause of significantly increased plasma homocysteine may be under-recognized by clinicians.
Introduction
Homocysteine is a sulphur containing amino acid that plays an important role in methionine metabolism. Hyperhomocysteinaemia is not a benign condition. Genetic enzyme defects or dietary de¢ciency of folate and other B group vitamins result in increased plasma homocysteine concentrations. Homocysteine is recognized as a marker of vascular disease risk 1 and a predictor of mortality in patients with established cardiovascular disease. 2 Hyperhomocysteinaemia has also been implicated in conditions as diverse as birth defects 3 and pregnancy complications, 4 cognitive impairment 5 and psychiatric conditions in the elderly, 6 and osteoporotic fractures. 7 The total concentration of homocysteine (tHcy) is a sensitive indicator of folate and vitamin B 12 status. 8, 9 The metabolic pathway for homocysteine removal requires folate, cobalamin (vitamin B 12 ) and pyridoxal (vitamin B 6 ). Possible causes of severe hyperhomocysteinaemia include hereditary disorders such as cystathionine b-synthase de¢ciency and disorders of folate or cobalamin metabolism, and acquired disorders such as cobalamin de¢ciency, folate de¢ciency, renal failure, and rarely acute lymphoblastic leukaemia. 9 Homozygosity for the methyltetrahydrofolate reductase (MTHFR) 677C-T polymorphism is the most common genetic determinant, but typically causes only a mild increase in tHcy concentrations. Individuals with the MTHFR 677TT variant usually have plasma tHcy values 2.5 mmol/L higher than those with the 677CC genotype. 10 Epidemiological data suggest that alcohol consumption can cause a modest increase in tHcy levels. 11--13 We report three cases of severe hyperhomocysteinaemia which were precipitated by high alcohol intake. Alcohol as a cause of signi¢cantly increased plasma tHcy may be under-recognized by clinicians.
Case one
A 66-year-old man of Italian descent was ¢rst referred to a lipid disorders clinic in December 2002. His past medical history was complex and included:
(1) Calcinosis, Raynaud's phenomenon, oesophageal dysfunction, sclerodactyly, and telangiectasia (CREST syndrome) complicated by severe digital ischaemia, with ulcers and amputation of the right middle ¢nger, despite previous sympathectomies; (2) Re£ux oesophagitis; In the course of investigation (Table 1) , the patient was found to have a markedly increased plasma tHcy of 107 mmol/L (reference interval 6--15; immunochemiluminometric assay, Immulite 2000, Diagnostic Products Corporation, Los Angeles, USA), total cholesterol 6.6 mmol/L (reference limit o5.5; Hitachi 917, Roche Diagnostics, Mannheim, Germany), triglyceride 13.1mmol/L (reference limit o1.8; Hitachi 917), alanine transaminase (ALT) 13 U/L (reference limit o41; Hitachi 917) and gamma glutamyl transferase (GGT) 40 U/L (reference limit o60; Hitachi 917). Apolipoprotein E (APOE) and MTHFR genotyping were performed (pyrosequencer HS 96, Pyrosequencing AB, Upsala, Sweden). Further investigation of the hyperhomocysteinaemia showed normal vitamin B 12 (Immulite 2000) and red cell folate (in-house microbiological assay) concentrations and preserved renal function.
Dietary advice was given. He consumed alcohol in excess and in a binge pattern (red wine up to 60 g alcohol daily). His hypertriglyceridaemia was treated with the combination of ¢brate and ¢sh oil. Increased tHcy was treated with B 6 , B 12 and folate supplementation orally. His other medications included irbesartan, pantoprazole and frusemide. Treatment compliance was not always ideal, principally due to communication di⁄culties (the patient was Italian speaking). Initial reduction in alcohol consumption and vitamin supplementation was accompanied by a reduction (but not normalization) of tHcy (23.8, 28.2, and 24.1 mmol/L; Figure 1 ). Unfortunately, the patient resumed heavy alcohol use and this was associated with increases in tHcy (93.4, 42.5, and146 mmol/L). After a further period of abstinence, the tHcy concentration fell once again to 27.9 mmol/L
Case two
A 51-year-old man was ¢rst seen in a diabetes clinic in April 2003. His past medical history included type 2 diabetes mellitus diagnosed in 1993 treated with gliclazide and complicated by peripheral neuropathy and erectile dysfunction. Other vascular risk factors were hypertriglyceridaemia and hypertension (treated with ramipril). He consumed alcohol in excess (beer equivalent to 150 g alcohol daily), and this was assumed to have been a contributor to previous episodes of pancreatitis and gout, as well as his hypertriglyceridaemia.
Biochemistry (Table 1 ) showed a signi¢cantly increased plasma tHcy concentration of 64 mmol/L, glycated haemoglobin A 1c 7.4% (reference interval 4--6; ion-exchange high-performance liquid chromatography, Bio-Rad, Hercules, USA), total cholesterol 7.8 mmol/L, triglyceride 17.8 mmol/L, ALT 53 U/L and GGT 652 U/L. APOE and MTHFR genotyping was performed. Investigation of the hyperhomocysteinaemia Figure 1 Plasma tHcy with time in the three cases. Reduction in alcohol consumption (self-reported) associated with a decrease in plasma tHcy concentrations. Resumption of heavy alcohol use for case one was associated with further increased tHcy values. Repeated advice regarding alcohol abstinence was associated with a fall in tHcy to 27.9 mmol/L. tHcy reference interval is indicated in grey (6-15 mmol/L).
con¢rmed normal concentrations of vitamin B 12 at 164 pmol/L, red cell folate at 1279 nmol/L and vitamin B 6 at 45 nmol/L (reference interval 23--59; in-house microbiological assay).
Advice regarding diet and alcohol was given. He was commenced on ¢sh oil 3 g daily for the hypertriglyceridaemia. Repeat biochemistry after self-reported reduction of alcohol consumption showed normalization of plasma tHcy to 7.0 mmol/L (Figure 1 ) with gradual improvement in his lipid pro¢le. After six months therapy with ¢sh oil, his total cholesterol and triglyceride concentrations were 4.8 and 0.7 mmol/L, respectively.
Case three
A 41-year-old man was referred to a lipid disorders clinic in May 2004. He had abnormal liver function and dyslipidaemia. A previous trial of a statin had caused worsening abnormalities of liver function necessitating cessation of the drug. There was a family history of dyslipidaemia with his father and one of his brothers on lipid-lowering therapy. Other medical history included depression and a probable transient ischaemic attack characterized by right arm weakness (transthoracic echocardiogram and cranial computerized tomography were normal, minimal intimal hyperplasia of the carotids was noted on Doppler ultrasonography).
On ¢rst presentation (Table 1) , his plasma tHcy was 47 mmol/L, total cholesterol 7.6 mmol/L and triglycerides 15.7 mmol/L. Liver function was abnormal with an ALT 219 U/L, GGT 768 U/L and ferritin 1850 mg/L (reference interval 30--620, Hitachi 917). A screen for common infectious, metabolic and autoimmune causes of liver dysfunction was negative. Vitamin B 12 and serum folate concentrations were normal. APOE and MTHFR genotyping were performed. Dietary advice was given, including reduction in alcohol consumption (he was consuming up to 80 g alcohol daily). Repeat assessment of plasma tHcy after selfreported reduction of alcohol use con¢rmed normalization with a reduction to 12.2 mmol/L (Figure 1 ).
Discussion
In addition to hyperhomocysteinaemia, all cases had dyslipidaemia characterized principally by marked hypertriglyceridaemia. This may represent an adverse e¡ect of alcohol. Moderate alcohol intake increases plasma triglyceride concentrations by approximately 6%. 14 Genetic susceptibility was not likely as none of the cases were homozygotes for e2, a receptor binding defective form of apoE. Homozygosity of the e2/2 genotype predisposes some patients to the development of familial dysbetalipoproteinaemia (type III hyperlipidaemia), a condition that requires additional genetic or environmental factors for full clinical expression. 15 Mild increases in plasma tHcy (15--30 mmol/L) may be seen in 10% of an adult population not receiving folate supplementation. Severe hyperhomocysteinaemia (430 mmol/L) is uncommon with a prevalence of less than 1% in the adult population. 9 Chronic alcohol abuse is increasingly recognized as a cause of mildly increased tHcy levels. 11--13 However, severe hyperhomocysteinaemia is less well documented, with a previous report of two cases 16 and a small series of 29 patients admitted for alcohol detoxi¢cation also showing severe hyperhomocysteinaemia in some of the subjects. 17 Given the high frequency of alcohol abuse in patient surveys, 18 it may be among the most common causes of both mild and severe hyperhomocysteinaemia in patients and the general population. With cessation of alcohol use, there is a reduction in plasma tHcy levels, 17 which was clearly demonstrated in our three cases.
Increased plasma tHcy concentrations arise as a result of direct and indirect e¡ects of alcohol, including secondary vitamin B 6 and folate de¢ciencies. Ethanol, speci¢cally its immediate metabolic product, acetaldehyde, directly inhibits methionine synthase activity in vitro, thus providing a mechanism to produce hyperhomocysteinaemia independent of vitamin status. 19 Porcine models show a compensatory increase in betaine-homocysteine methyltransferase, although this e¡ect may be less prominent in humans. 20 Methionine concentrations vary, but S-adenosylmethionine synthetase activity is generally increased with a resultant diminution of hepatic S-adenosylmethionine levels. S-adenosyl homocysteine concentrations rise, and thus the S-adenosylmethionine:S-adenosyl homocysteine ratio, an important determinant of methylation activity has been consistently decreased.
Acetaldehyde also accelerates the intracellular degradation of pyridoxal-5 0 -phosphate, resulting in decreased hepatic pyridoxal-5 0 -phosphate content despite adequacy of vitamin B 6 dietary intake. 21 Cystathionine b-synthase and cystathionine lyase are pyridoxal-5 0 -phosphate-dependent enzymes, and as such alcohol metabolism can compromise homocysteine transsulphuration.
Human data are sparse, and in chronic alcoholism often complicated by liver disease and dietary insu⁄ciencies. Thus, the exacerbation of hyperhomocysteinaemia in case one despite supplementation with vitamin B 6 , vitamin B 12 and folate is of interest. This supports the acute elevation of homocysteine being mediated by alcohol-induced inhibition of transmethylation and transsulphuration pathways.
While the hyperhomocysteinaemia that accompanies chronic alcohol use is usually mild, it is not known if the sometimes severe hyperhomocysteinaemia represents simply a quantitative variation on the e¡ect of modest alcohol use or a qualitative di¡erence on homocysteine metabolism. The nature of the interaction between modest alcohol ingestion and homocysteine is poorly understood. Direct, inverse and 'U'-shaped relationships have been described, and there may be modi-¢cation by the type of alcoholic beverage, vitamin status and a variety of genetic factors. 12, 13, 22 The circumstances that convert mild into severe hyperhomocysteinaemia in chronic alcohol use are unknown. The observations in our patients suggest that neither polymorphisms of MTHFR nor vitamin B 6 , vitamin B 12 or folate de¢ciencies are likely explanations. In chronic alcohol use, the severity of any underlying liver disease does not correlate with the degree of hyperhomocysteinaemia, such that patients without evidence of cirrhosis can have severe hyperhomocysteinaemia. 16 Moreover, in the setting of alcohol detoxi¢cation, serum ethanol concentrations directly correlate with homocysteine levels. 17 The e¡ect of alcohol on homocysteine metabolism is complex and remains incompletely understood. Alcohol abuse may be a common cause of hyperhomocysteinaemia that is potentially severe and can £uctuate. Clinicians should be alerted to this possibility when evaluating patients with hyperhomocysteinaemia.
